55 results about "Bone metastasis" patented technology

The application relates to the field of image processing and discloses a bone metastasis detection and positioning system and method based on SPECT bone imaging. The system extracts and processes multi-scale features of a to-be-detected image through a feature pyramid network to obtain a multi-scale feature map; then extracts metabolic features, morphological features and uptake mode features from the multi-scale feature map through a bone-specific feature model, and gradually fuses the metabolic features, the morphological features and the uptake mode features to obtain a bone-specific enhanced feature map; then extracts and fuses features of the bone-specific enhanced feature map through a mixed feature fusion model to obtain mixed fusion features; finally, the mixed fusion features are subjected to probability reasoning and double-uncertainty quantization processing through a probability reasoning network to determine a bone metastasis detection result, high-precision detection and positioning of bone metastasis lesions are realized, and the problems that existing technologies cannot effectively identify different size lesions and lack global perception ability are effectively solved.

The application discloses a prostate cancer bone metastasis risk prediction diagnosis device and relates to the technical field of prostate cancer diagnosis. The application comprises a diagnosis table, two support rods are symmetrically arranged on one side of the diagnosis table, support plates are arranged on the sides of the two support rods away from each other, an adjusting assembly for adjusting the positions of the support plates is arranged on the support rods, a connecting block is fixed at one end of the diagnosis table, a movable groove is arranged in the connecting block, movable blocks are fixed at the bottom ends of the support rods, and the movable blocks are slidably connected in the movable groove. When rectal digital examination is needed for a patient, the patient is laid on the diagnosis table, the bent parts of the legs of the patient are respectively arranged on the two support plates, the two movable blocks are driven to move away from each other through a driving mechanism, the legs of the patient are bent and separated, and the patient is in a supine position, so that rectal digital examination in a supine position is facilitated.

The application discloses application of an inhibitor targeting SLC7A7 in preparation of a drug for treating lung cancer bone metastasis, and the inhibitor targeting SLC7A7 is a small molecule compound SLCi18. The application firstly verifies high expression of SLC7A7 in lung cancer bone metastasis cells and lung cancer bone metastasis clinical tissues, and silencing the expression of SLC7A7 can inhibit the development of lung cancer bone metastasis; the small molecule compound SLCi18 as the inhibitor targeting SLC7A7 can inhibit the function of SLC7A7 in transporting methionine, and inhibit lung cancer bone metastasis; and the application provides a new target and treatment strategy for lung cancer bone metastasis.

The invention is suitable for the technical field of medical image processing and artificial intelligence, and provides a urinary system tumor bone metastasis diagnosis method based on deep learning and bone positioning, and the method comprises the steps: collecting and preprocessing multi-modal medical data containing PET / CT images; segmenting a skeleton region by adopting a deep learning model, and realizing focus segmentation in the skeleton region; a lightweight skeleton segmentation network is constructed, and efficient and fine skeleton segmentation is realized through an encoder-decoder structure; pET metabolic features, CT morphological features and texture features are extracted and fused, and a radiomics feature matrix is constructed; carrying out cancer species specificity analysis based on the radiomics characteristic matrix, and constructing an intelligent diagnosis model by utilizing a machine learning algorithm; and finally, outputting a structured report containing the focus position, the type, the cancer classification and the diagnosis confidence. According to the invention, through lightweight network design and multi-modal feature fusion, the efficiency and accuracy of skeleton segmentation and focus diagnosis are significantly improved, and the method is suitable for clinical real-time auxiliary diagnosis.

The invention belongs to the technical field of gene detection, and particularly relates to a prostate cancer bone metastasis diagnostic kit based on gene methylation detection and application of the prostate cancer bone metastasis diagnostic kit. The invention proves that the bone metastasis and non-bone metastasis of the prostate cancer can be effectively distinguished by PCR methylation detection or joint detection based on AKR1B1, RASSF2 and other genes, and a new thought is provided for clinical diagnosis and typing of the bone metastasis of the prostate cancer.

The application discloses a kind of whole body SPECT lung cancer bone imaging data processing method and system, it is related to image processing technical field, comprising: the whole body SPECT lung cancer bone imaging data is input into the improved UNet network after training, local texture feature is extracted by profile wave decomposition module, local texture feature is fused with original image, and the image feature is extracted by inputting fusion feature into UNet encoder;Using the UNet decoder of adding profile wave feature splicing and reconstruction strategy to the extracted image feature, obtains lung cancer bone metastasis lesion area.The application can improve the feature extraction capability of bone imaging lesion segmentation method under low resolution and fuzzy boundary condition.

The invention belongs to the technical field of bioengineering, and discloses a method for constructing a bone-affinity mouse hepatoma cell line with bone metastasis characteristic, which comprises the following steps: digesting a mouse hepatoma cell line Hepa1-6 with pancreatin for 5 minutes, adding into a complete medium to stop digestion, centrifuging for 5 minutes at normal temperature by 300g, resuspending into 1 million cells / 100mu l by using PBS, and transferring into a 1.5 ml EP tube; after the mouse is anesthetized, shaving off hair at the chest of the mouse by using a shaver with the abdomen facing upwards, fixing the mouse on an operation table, sucking 100 [mu] l of cell suspension by using an insulin needle, inserting the needle from the intersection point of the left-side xiphoid process and the lower costal margin, and slowly injecting cells after active blood return is seen; the bone metastasis formation condition of the lower limb bone Hepa1-6 of the mouse is monitored regularly through an SPECTRAL Lago X small animal living body imaging system, isoflurane is used as an anesthetic, and it is guaranteed that the shooting time and the exposure condition of each time of monitoring are consistent; after obvious bone metastasis is formed, obvious mobility inconvenience of the mouse is observed; through multi-generation in-vivo screening, the mouse liver cancer cell line with strong bone affinity is obtained.

The application belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating lung cancer bone metastasis and application thereof. The main active ingredients of the traditional Chinese medicine composition include, in mass parts, 20-40 parts of radix codonopsis, 20-40 parts of poria, 20-40 parts of astragalus, 10-30 parts of atractylodes, 10-20 parts of licorice, 10-30 parts of curcuma, 10-20 parts of pinellia, 5-10 parts of dried tangerine or orange peel, 20-40 parts of oldenlandia, 10-30 parts of psoralea, 10-30 parts of drynaria, 10-30 parts of epimedium, and 10-20 parts of jackinthepulp. Animal experiments show that the traditional Chinese medicine composition can not only inhibit primary tumor growth, but also slow down tumor progression of bone metastasis. When combined with a chemotherapy drug, the traditional Chinese medicine composition can not only significantly enhance the tumor inhibition effect of the chemotherapy drug, but also significantly prolong the survival time of mice, relieve weight loss and organ toxic side effects caused by the chemotherapy drug.

The invention discloses a drug for combined treatment of breast cancer bone metastasis, the drug comprises two active components, namely a first active component and a second active component, the first active component is Bufalin and its pharmaceutically acceptable salt, prodrug and derivative, and the second active component is RANKL targeted drug; bufalin and a derivative thereof are combined with an RANKL targeted drug for use, the Bufalin and the derivative thereof are synergistically complementary, and the Bufalin is used for regulating and controlling a tumor microenvironment, reducing secretion of high bone metastatic breast cancer cells HMGB1 and inhibiting differentiation of mononuclear / macrophages in bone marrow to osteoclasts, so that occurrence and development of breast cancer bone metastasis are inhibited; the RANKL targeted drug can specifically block an OPG / RANK / RANKL signal channel, inhibit osteoclast activation, reduce bone destruction and block vicious circle of bone metastasis; when the two active ingredients are combined for use, the effect of inhibiting breast cancer bone metastasis is obviously better than that of single use of any active ingredient, the occurrence of breast cancer bone metastasis can be effectively prevented and delayed, the progress of bone metastasis focus is controlled, and the occurrence risk of bone related events is reduced.

The present application relates to a marker IBSP of lung cancer bone metastasis and application thereof. Specifically, the present inventors found that IBSP is highly expressed in both plasma and bone metastasis foci of lung cancer patients, and positively correlates with bone metastasis, thus can be used as a biomarker for detecting and diagnosing bone metastasis. Further studies have proved that the differentiation of macrophages to osteoclasts induced by IBSP is a necessary and sufficient condition for promoting lung cancer bone metastasis, thus IBSP inhibitors can inhibit bone metastasis. In addition, the present inventors first found that IBSP can directly induce the positive differentiation of macrophages to osteoclasts by regulating the Rac1-NFAT signaling pathway, thus inhibiting Rac1 can block the lung cancer bone metastasis induced by IBSP. The present application provides an effective target for diagnosing and treating lung cancer bone metastasis, and provides a new method for the prevention, diagnosis and treatment of bone metastasis.

The application relates to the technical field of tumor biology, and particularly discloses a screening method of a candidate compound for reducing docetaxel resistance of prostate cancer patients and application. The screening method comprises the following steps: detecting the influence of a compound on the combination of B-cell lymphoma-2 protein and UBR family protein IV; and when the compound promotes the combination of B-cell lymphoma-2 protein and UBR family protein IV, the compound is a candidate compound. The application screens the candidate compound for reducing docetaxel resistance of prostate cancer patients by detecting the influence of the compound on the combination of B-cell lymphoma-2 protein and UBR family protein IV, so that the intrinsic and adaptive DTX resistance induced by TGF-beta in PCa bone metastasis is overcome.

The invention relates to a nano compound loaded with EZH2siRNA and docetaxel, which is characterized in that a zeolite imidazole skeleton (ZIF-8) is used as a carrier for siRNA delivery, then siRNA (ZIF)-8NPs is coated by using double-layer lipid, and meanwhile, the docetaxel (DTXL) is loaded in the double-layer lipid. The nano-composite loaded with EZH2siRNA and docetaxel has the beneficial effects that 1, the nano-composite loaded with EZH2siRNA and docetaxel is small in side effect as a drug, and the drug distribution at the bone metastatic focus of prostate cancer is relatively good; 2, the ZIF-8 has strong positive charges and can effectively adsorb siRNA with negative charges; 3, the nano drug loading system with a core-shell structure can more efficiently co-deliver siRNA and docetaxel, the core structure ZIF-8 can effectively load siRNA, and a shell lipid bilayer can effectively deliver a chemotherapeutic drug DTXL; and 4, the nano-composite loaded with the EZH2siRNA and the docetaxel is used as a medicine, so that the targeting property is high, and alendphosphate groups in middle and outer layer lipid DOPE-PEG-Alendronate can be effectively distributed to bone metastasis lesion in a targeting manner.

The invention relates to a tumor bone metastasis prediction system and method based on a bone metastasis specific bone marker. The system comprises a calculation module used for calculating the sensitive weight of each common marker for the same cancer according to the metabolic rate of a plurality of patients for each common marker and the number of the plurality of patients; the compensation module is used for determining a compensation coefficient of each specific marker for the same cancer on the basis of the difference between the detection value of each specific marker of the same patient and historical detection data; the determining module is used for determining a target coupling coefficient of each specific marker according to the relevancy between each specific marker and each common marker of the plurality of patients; and the analysis module is used for carrying out risk analysis according to the sensitive weight, the compensation coefficient, the target coupling coefficient and the target growth speed of each common marker to obtain an analysis result. According to the application, the change synchronism of the common marker and the specific marker can be quantified, the early bone metastasis detection capability is improved, and the misjudgment rate is reduced.

The invention relates to the field of image processing, and discloses a bone metastasis detecting and positioning system and method based on SPECT bone imaging. The system performs multi-scale feature extraction and feature processing on a to-be-detected image through a feature pyramid network to obtain a multi-scale feature map; then, metabolic features, morphological features and uptake mode features are extracted from the multi-scale feature map through a bone specificity feature model, and progressive fusion is carried out on the metabolic features, the morphological features and the uptake mode features to obtain a bone specificity enhanced feature map; performing feature extraction and feature fusion on the bone specificity enhanced feature map through a mixed feature fusion model to obtain mixed fusion features; and finally, probabilistic reasoning and dual uncertainty quantification processing are carried out on the mixed fusion features through a probabilistic reasoning network, a bone metastasis detection result is determined, high-precision detection and positioning of bone metastasis lesions are achieved, and the problems that in the prior art, lesions of different sizes cannot be effectively recognized, and global perception ability is lacked are effectively solved.

The aqueous pharmaceutical formulation with improved stability comprises denosumab and a poloxamer, and preferably a histidine buffer and / or a sugar or sugar alcohol. The formulation is for use in the treatment or prevention of skeletal-related events associated with osteoporosis, reduced bone mass, multiple myeloma, solid tumor bone metastasis, giant cell tumor of bone, or hypercalcemia.

The application relates to a tumor bone metastasis prediction system and method based on bone metastasis specific bone markers. The system comprises a calculation module, which calculates the sensitive weight of each common marker for the same cancer according to the metabolic speed of each common marker of a plurality of patients and the number of the plurality of patients; a compensation module, which determines the compensation coefficient of each specific marker for the same cancer based on the difference between the detection value of each specific marker of the same patient and historical detection data; a determination module, which determines the target coupling coefficient of each specific marker according to the correlation between each specific marker and each common marker of a plurality of patients; and an analysis module, which performs risk analysis according to the sensitive weight, the compensation coefficient, the target coupling coefficient and the target growth speed of each common marker to obtain an analysis result. The application can quantify the synchronism of the changes of the common markers and the specific markers, improve the early bone metastasis detection capability and reduce the misjudgment rate.

The present application discloses a bone-targeting radiopharmaceutical or imaging agent and a use thereof. The bone-targeting radiopharmaceutical or imaging agent can be used for the treatment or diagnosis of bone diseases, such as bone metastasis from a tumor.

The invention belongs to the technical field of tumor model construction, and discloses a lung adenocarcinoma animal model with high bone metastasis, a cell line and a construction method and application thereof. The lung adenocarcinoma animal model with high bone metastasis is provided through multi-generation in-vivo directional screening, and the construction method is efficient, controllable, high in repeatability, capable of remarkably improving the tumor formation efficiency and rate, capable of being applied to immune healthy mice, low in cost and high in stability. And further extracting tumor cells from the bone metastasis lesion of the animal model to obtain the mouse lung adenocarcinoma cell line with high bone metastasis. The cell line has the advantages of being excellent in bone metastasis performance, stable in phenotype, heritable and the like, can be connected with an existing research system, has universality and economical efficiency, and can efficiently meet the requirement of bone metastasis mechanism research on a high-specificity model. The method can be applied to the fields of construction of tumor animal models or cell lines of bone metastasis, screening or development of lung adenocarcinoma drugs and the like.

The invention relates to a multi-target molecular ligand as well as a preparation method and application thereof. The multi-targeting molecular ligand disclosed by the invention aims at prostate cancer and bone metastasis thereof, and the ligand simultaneously contains a polypeptide chain Glu-urea-Lys (ACUPA) capable of being recognized by a prostate specific membrane antigen (PSMA), is used for targeting diphosphoric acid of hydroxyapatite nanocrystals in bones, and is also combined with an anisidine fragment which is specifically combined with a Sigma-1 receptor. The multi-target molecular ligand can efficiently mark radionuclide and has excellent radiation stability, cell and animal experiments prove that the multi-target molecular ligand can be efficiently taken by PSMA positive prostate cancer RM-1 cells, RM-1 subcutaneous tumor models and RM-1 tibial metastatic tumor models, and can be used for developing diagnosis and treatment of PSMA positive prostate cancer and bone metastasis thereof, and diagnosis and treatment integration is achieved.

The application discloses a marker for diagnosing, treating and / or prognosing prostate cancer bone metastasis and application thereof. The application discloses the relationship between LCAL4 and prostate cancer bone metastasis for the first time. The application verifies that LCAL4 is highly expressed in bone metastatic tumor tissues by using fluorescent quantitative PCR, and indicates a shorter bone metastasis-free survival time. In addition, it is also proved by in-vivo and in-vitro experiments that the down-regulation of LCAL4 gene expression can significantly inhibit the'stem cell characteristics' of prostate cancer cells, thereby inhibiting the bone metastasis of tumor cells. The application also designs an ASO sequence for inhibiting the expression of LCAL4 gene, and adopts a gene therapy method to make LCAL4 to silence the expression of LCAL4 at a cancerous site, so that the application can be used for preparing a drug for preventing and / or treating prostate cancer bone metastasis.

The application provides a tumor bone metastasis prediction system and method based on bone metastasis specific bone markers, relates to the technical field of machine learning, and comprises the following steps: an index acquisition module is used for acquiring a plurality of bone marker indexes related to bone metastasis in patient serum obtained by serum detection of a patient; and a bone metastasis prediction module is connected to the index acquisition module, used for inputting each bone marker index into a tumor bone metastasis prediction model trained in advance, so as to predict the early bone metastasis incidence of the patient, thereby providing a reference for clinical diagnosis by doctors. The beneficial effect is that the bone marker content of calcium and phosphorus metabolism regulation indexes, bone formation and bone resorption markers, bone metabolism related hormones and cytokines, and electrolytes in serum is quantitatively detected, and the early bone metastasis incidence is predicted through machine learning, so that the method can be used for early auxiliary diagnosis of tumor bone metastasis, auxiliary evaluation of curative effect in a treatment process and monitoring of metastasis recurrence after treatment, and the detection result can be earlier than clinical symptoms.

The invention discloses a construction method and application of a lung cancer bone metastasis non-human animal model. The construction method comprises the following steps: step 1, constructing a Rosa26 fixed-point human-derived SLC7A7 conditional overexpression mouse model; 2, the R26LSL-slc7a7 homozygous mouse and KrasLSL-G12D / + are subjected to a reaction, and the mouse is subjected to a reaction; the method comprises the following steps: carrying out mating on a Tp53flox / flox mouse, carrying out multiple times of selfing on the obtained heterozygote to obtain a KPS mouse, and delivering an effective dose of Cre recombinase to the lung of the mouse. The invention successfully constructs a genetic engineering animal model capable of inducing three-gene collaborative manipulation, the model can efficiently and stably simulate the whole process of lung adenocarcinoma generation, development and distal bone metastasis, and provides a foundation for deeply exploring the pathogenic mechanism of lung cancer bone metastasis, exploring novel diagnostic markers and developing efficient anti-tumor drugs. And a stable and reliable experimental tool with good clinical correlation is provided.

This invention provides a nucleic acid aptamer that targets and binds to the IGF2BP2 protein and its application, belonging to the field of pharmaceutical technology. This invention is the first to design a highly specific nucleic acid aptamer targeting the RNA recognition protein IGF2BP2, obtaining a nucleic acid aptamer that can target and specifically bind to the IGF2BP2 protein (see SEQ ID No. 1-2). This nucleic acid aptamer can effectively inhibit the activity of tumor cells, tumor stem cells, and breast cancer brain metastases, breast cancer lung metastases, breast cancer liver metastases, breast cancer kidney metastases, and breast cancer bone metastases, providing a new drug component for the treatment of malignant and refractory tumors (especially glioblastoma and distant metastatic breast cancer). Furthermore, it was discovered that modification with N6-methyldeoxyadenosine monophosphate can further enhance the specificity of the nucleic acid aptamer and strengthen its efficacy in inhibiting tumor cell activity.

The present application belongs to the field of biomedicine, and particularly relates to the application of fibroblasts in lung cancer prognosis; and specifically discloses the use of ANXA6 gene in the preparation of a preparation for diagnosing bone metastasis in a subject with lung cancer in vitro and / or for predicting the tendency of forming bone metastasis in a subject with lung cancer in vitro, wherein when overexpression of the ANXA6 gene in CAF is detected, the subject is positively diagnosed with metastasis or has a greater tendency of forming metastasis.

The application discloses a kind of biomimetic 3D printing hydrogel scaffold and its preparation method and application, belong to medical instrument technical field.The biomimetic 3D printing hydrogel scaffold includes 3D printing hydrogel scaffold and in 3D printing hydrogel scaffold surface imitating mussel catalytic coating;The biological ink of 3D printing hydrogel scaffold includes methacrylated gelatin, calcium ion pre-crosslinking sodium alginate, dendritic cell-derived exosome loaded with STING agonist and methacrylated modified osteogenic growth peptide;Imitate mussel catalytic coating is by polydopamine layer and the dopa-manganese metal polyphenol network nanoenzyme loaded on the surface of polydopamine layer jointly constitute.By the synergistic effect of each component, effectively solve the technical problem that existing scaffold lacks time sequence treatment mechanism, realize the dual effect of tumor removal and bone defect repair in bone metastasis tumor treatment.

The invention belongs to the technical field of biology and oncology, and particularly relates to a high altitude bone metastatic prostate cancer cell line as well as a construction method and application thereof. In the invention, the plateau bone metastatic prostate cancer cell strain is named as mouse prostate cancer cell RM1-BM3, and the preservation number is CCTCC (China Center For Type Culture Collection) NO: C2025126. The invention also provides a construction method of the high altitude bone metastatic prostate cancer cell line. The invention also discloses application of the plateau bone metastatic prostate cancer cell line in establishing a mammal prostate cancer model, extracting prostate cancer bone metastasis and recurrence markers, evaluating the efficacy of prostate cancer drugs, developing the prostate cancer drugs and preparing prostate cancer diagnostic reagents, and a solid foundation is laid for subsequent exploration of a prostate cancer bone metastasis mechanism.

The invention belongs to the technical field of medicine, and discloses an application method of CLIC3 as a serological molecular marker in prediction of lung cancer bone metastasis, CLIC3 is significantly increased in serum of patients with lung cancer bone metastasis, and the total lifetime and non-metastasis lifetime of lung cancer patients with high expression of CLIC3 are significantly shorter than those of patients with low expression. In addition, bone metastasis in a mouse model constructed by CLIC3 high-expression lung cancer cells is remarkably enhanced. Based on detection and analysis of clinical specimens, it is successfully identified that CLIC3 can serve as a brand new serum marker and has a key indication effect in the aspect of early warning of lung cancer bone metastasis. In the research process, multi-dimensional verification is carried out by comprehensively applying a bioinformatics technology, molecular biology detection, a mouse animal model and other methods, and the serum CLIC3 has outstanding potential early warning efficiency and is expected to serve as a novel biological marker with innovativeness, scientificity and clinical application prospects in the early warning category of lung cancer bone metastasis.

The invention discloses application of a diaryl-substituted alpha-carbonyl amide compound. The diaryl-substituted alpha-carbonyl amide compound can be used for preparing medicines for treating osteoporosis, tumor bone metastasis or inflammatory bone destruction. Cell experiments prove that the diaryl-substituted alpha-carbonyl amide compound Z1-Z4 provided by the invention has a remarkable inhibition effect on osteoclast differentiation and bone resorption induced by RANKL, has no obvious cytotoxicity, and can be used as a candidate drug with a novel structure for inhibiting osteoclast differentiation and bone resorption; the method is used for targeting osteoclast to treat bone mass loss related diseases.